Janssen reports PALMFlexS trial results of schizophrenia drug Xeplion

Janssen Pharmaceutica has reported encouraging results from the PALMFlexS study, which demonstrated the efficacy, safety and tolerability of Xeplion (paliperidone palmitate) in patients with schizophrenia at various stages of the disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news